As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Stocks that are in favor and making large moves is a segment of the market that I tweet about on a regular basis.These are also the exact type of stocks that I love to trade and alert to my subscribers in real-time.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Rennova Health

  • Tuesday's Range: $0.67-$0.78
  • 52-Week Range: $0.52-$9.30
  • Tuesday's Volume: 253,000
  • Three-Month Average Volume: 72,102

Rennova Health  (RNVA)  provides diagnostics and supportive software solutions to health care providers in the U.S. This stock closed up 15.6% to 78 cents per share in Tuesday's trading session.

From a technical perspective, Rennova Health exploded sharply higher on Tuesday right off its 50-day moving average of 67 cents per share and back above its 20-day moving average of 71 cents per share with strong upside volume flows. Market players should now look for a continuation move higher in the short-term if this stock manages to clear Tuesday's intraday high of 78 cents with high volume.

Traders should now look for long-biased trades in Rennova Health long as it's trending above its 20-day moving average of 71 cents per share and then once it sustains a move or close above Tuesday's intraday high of 78 cents per share with volume that hits near or above 72,102 shares. If that move gets underway soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at 89 to 90 cents, or even around $1.10 to $1.16 a share.

Tandem Diabetes Care

  • Tuesday's Range: $7.22-$7.71
  • 52-Week Range: $6.48-$13.48
  • Tuesday's Volume: 260,000
  • Three-Month Average Volume: 212,875

Tandem Diabetes Care  (TNDM - Get Report) , a medical device company, designs, develops and commercializes various products for people with insulin-dependent diabetes in the U.S. This stock traded up 1% to $7.59 in Tuesday's trading session.

From a technical perspective, Tandem Diabetes spiked notably higher on Tuesday right off its 20-day moving average of $7.21 a share with above-average volume. This high-volume bump to the upside is now quickly pushing shares of Tandem Diabetes within range of triggering a major breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $7.87 a share to its 50-day moving average of $8.03 a share with high volume.

Traders should now look for long-biased trades in Tandem Diabetes as long as it's trending above its 20-day moving average of $7.21 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 212,875 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at around $8.50 to its 200-day moving average of $9.20 a share.

Tonix Pharmaceuticals

  • Tuesday's Range: $1.87-$2.18
  • 52-Week Range: $1.84-$10.72
  • Tuesday's Volume: 1.54 million
  • Three-Month Average Volume: 358,411

Tonix Pharmaceuticals  (TNXP)  engages in developing medicines for common disorders of the central nervous system. This stock traded up 5.6% to $2.05 in Tuesday's trading session.

From a technical perspective, Tonix Pharmaceuticals spiked sharply higher on Tuesday and broke out into its previous gap-down-day zone with heavy upside volume flows. This stock recently gapped-down from around $2.65 a share to under $2 a share with heavy downside volume flows. Shares of Tonix Pharmaceuticals have now reversed its recent downtrend and started to flirt with that gap on strong upside volume. Market players should look for a continuation move to the upside in the short-term if this stock manages to clear Tuesday's intraday high of $2.18 a share with high volume.

Traders should now look for long-biased trades in Tonix Pharmaceuticals as long as it's trending above Tuesday's intraday low of $1.87 a share and then once it sustains a move or close above Tuesday's intraday high of $2.18 a share with volume that hits near or above 358,411 shares. If that move gets underway soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 20-day moving average of $2.40 a share to its 50-day moving average of $2.50 a share, or even $2.65 a share.

Axsome Therapeutics

  • Tuesday's Range: $6.08-$6.90
  • 52-Week Range: $5.37-$15.74
  • Tuesday's Volume: 41,000
  • Three-Month Average Volume: 30,502

Axsome Therapeutics  (AXSM) , a clinical stage biopharmaceutical company, develops therapies for the management and treatment of central nervous system disorders. This stock traded up 8.2% to $6.68 in Tuesday's trading session.

From a technical perspective, Axsome Therapeutics ripped sharply higher on Tuesday right off some near-term support at $6.06 a share with above-average volume. This stock has been downtrending badly over the last two months, with shares moving lower off its high of $12.69 to its recent low of $6.06 a share. During that downtrend, shares of Axsome Therapeutics have been consistently making lower highs and lower lows, which is bearish technical price action. That said, this stock has now started to rebound off that $6.06 low, and it's starting to move within range of triggering a near-term breakout trade. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $6.90 to $7.10 a share and then above more key resistance at $7.32 a share with high volume.

Traders should now look for long-biased trades in Axsome Therapeutics as long as it's trending above its recent low of $6.06 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 30,502 shares. If that breakout develops soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 20-day moving average of $7.66 to $8.66, or even $9 to its 50-day moving average of $9.43 a share.

Lipocine

  • Tuesday's Range: $6.46-$6.98
  • 52-Week Range: $6.41-$19.23
  • Tuesday's Volume: 573,000
  • Three-Month Average Volume: 229,552

Lipocine  (LPCN) , a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. This stock traded up 2.2% to $6.96 in Tuesday's trading session.

From a technical perspective, Lipocine spiked notably higher on Tuesday right off its new 52-week low of $6.41 a share with strong upside volume flows. This stock has been downtrending over the last few weeks, with shares sliding lower off its high of $9.59 a share to its new 52-week low of $6.41 a share. During that downtrend, shares of Lipocine have been consistently making lower highs and lower lows, which is bearish technical price action. That said, this stock has now started to bounce off that $6.41 low with volume, and it's quickly trending within range of triggering a near-term breakout trade. That trade will trigger if this stock manages to take out Tuesday's intraday high of $6.98 a share and then once it clears more key resistance at $7.20 a share with high volume.

Traders should now look for long-biased trades in Lipocine as long as it's trending above its new 52-week low of $6.41 a share and then once it sustains a move or close above those breakout levels with volume that registers near or above 229,552 shares. If that breakout takes hold soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $7.80 to around $8, or even its 20-day moving average of $8.32 to around $8.50 a share.

Square

  • Tuesday's Range: $9.12-$9.38
  • 52-Week Range: $8.06-$15.91
  • Tuesday's Volume: 2.59 million
  • Three-Month Average Volume: 3.48 million

Square  (SQ - Get Report)  develops and provides payment processing, point-of-sale, financial and marketing services worldwide. This stock traded up 1.6% to $9.35 in Tuesday's trading session.

From a technical perspective, Square jumped modestly higher on Tuesday right above some near-term support at around $9 a share with decent upside volume flows. This stock recently formed a double bottom chart pattern, after shares found some buying interest at $8.63 to $8.64 a share. Following that potential bottom, shares of Square have now started to spike higher right into its 20-day moving average of $9.42 a share. That spike is now quickly pushing this stock within range of triggering a big breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at its 20-day moving average of $9.42 a share and then above more resistance at around $9.70 a share with high volume.

Traders should now look for long-biased trades in Square as long as it's trending above some near-term support at around $9 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 3.48 million shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $10 to $10.22, or even $10.50 to its gap-down-day high from May at $11.19 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.